Thursday, May 8, 2014
The Temple University School of Pharmacy
has teamed up with MorphoSys AG to bring
industry-quality antibody technology in-house. The partnership expands
MorphoSys' access to early stage research and adds to the toolkit of discovery
capabilities at the Moulder Center for Drug Discovery Research at Temple
On the heels of the small molecule deals, Abou-Gharbia
said that the next logical step was to expand the center's biologic
capabilities. To do this, he recruited Jon Condra in September 2012 to head a
new Biotherapeutics Discovery Unit.
Cain, C. SciBX 7(18);
Published online May 8, 2014
S. SciBX 4(33); doi:10.1038/scibx.2011.923
C. BioCentury 20(5), A9-A10; Jan. 30, 2012
COMPANIES AND INSTITUTIONS MENTIONED
Cortendo AB, Gothenburg, Sweden
The Johns Hopkins University School of Medicine, Baltimore, Md.
Merck & Co. Inc. (NYSE:MRK), Whitehouse Station,
MorphoSys AG (Xetra:MOR; Pink:MPSYF), Martinsried, Germany
Moulder Center for Drug Discovery Research at Temple
Shifa Biomedical Corp., Malvern, Pa.
Temple University School of Pharmacy, Philadelphia, Pa.
Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass.
University of Nebraska Medical Center, Omaha, Neb.
University of Rochester Medical Center, Rochester, N.Y.
The Wistar Institute, Philadelphia, Pa.